<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699305</url>
  </required_header>
  <id_info>
    <org_study_id>RD005</org_study_id>
    <nct_id>NCT04699305</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers</brief_title>
  <official_title>An Observational Clinical Registry to Collect Safety and Efficacy Data on Wound Care in Medical Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedDress Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedDress Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter observational study to explore the efficacy of ActiGraft in the treatment of&#xD;
      exuding cutaneous wounds in real-life usage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Percentage area reduction (PAR) at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature, frequency, and severity of adverse events in the intent to treat population</measure>
    <time_frame>1 year</time_frame>
    <description>Nature, frequency, and severity (by CTCAE5) of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage area reduction at 8 and 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline at 8 and 12 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reduction in pain at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain reduction at 4 weeks for wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT) for patients reporting any level of wound related pain (&gt;1 on a VAS scale of 0-10 points) at baseline</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cutaneous Wounds</condition>
  <arm_group>
    <arm_group_label>ActiGraft</arm_group_label>
    <description>Whole blood clot (WBC) gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiGraft</intervention_name>
    <description>Whole blood clot (WBC) gel</description>
    <arm_group_label>ActiGraft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with all types of exuding cutaneous wound&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is â‰¥18 years of age&#xD;
&#xD;
          -  Subject has an exuding cutaneous wound&#xD;
&#xD;
          -  Subject agrees to the use of his health data, including photos of his wound in&#xD;
             analysis and publications&#xD;
&#xD;
          -  Subject/LAR must be able to read and understand English and/or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject/LAR is unable to read and understand English or Spanish.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sharon Sirota</last_name>
    <role>Study Director</role>
    <affiliation>RedDress Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Sirota</last_name>
    <phone>+972545800765</phone>
    <email>sharon@reddress.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wound Care Experts</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naz Wahab, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DFU, PU, Surgical, Vascular, Trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results will be part of several scientific publications</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Upon publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

